CABA-201: Clinical Trials

1 trial of CABA-201, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21Recruiting 1
Phase 31Recruiting 1

Follow CABA-201: new trials by email Literature Review of CABA-201 trials Research Report on CABA-201

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
CABA-201 - Systemic Sclerosis, Scleroderma
Phase 2 / Phase 3RecruitingCabaletta Bio372024-07-022026-10-16

Conditions studied

Autoimmune Diseases (1)  ·  Lung Diseases, Interstitial (1)  ·  Scleroderma, Diffuse (1)  ·  Scleroderma, Systemic (1)

Sponsors

Cabaletta Bio (1)

Countries

United States (1)